The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 352:2030-2031 May 12, 2005 Number 19
NextNext

Antibody Response to Aerosolized Transgenic Human Alpha1-Antitrypsin

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: The Department of Health and Human Services has recommended the development of recombinant counterparts to blood-derived therapeutic human proteins.1 In response to this recommendation, sheep-derived transgenic human alpha1-antitrypsin (AAT) was developed for aerosolized delivery to the lungs. A flock of AAT-transgenic sheep was established by means of the nuclear transfer into sheep ova of normal human AAT complementary DNA linked to the sheep {beta}-lactoglobulin promoter.2 Human AAT was isolated from whey from the milk of transgenic sheep and purified (99.9 percent) by sequential chromatography. The major impurities in the final product were sheep AAT and sheep . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.